The outcry continues over the $1,000-a-pill hepatitis C drug made by California-based Gilead Sciences.
While the drug is a significant advance over older treatments
for the viral liver disease, the price set by the company “represents an
abuse of market power,” said John Rother, president and CEO of the
National Coalition on Health Care, which includes businesses, unions,
insurers, consumers and some drugmakers, including Teva Pharmaceuticals
and the Generic Pharmaceutical Association.
On Wednesday, the group urged a “national dialogue” on
the cost, saying Sovaldi’s price tag threatens the budgets of
government run-health programs as well as the premiums for everyone who
has private insurance.